Logo

PODD

Insulet Corporation

PODD

Insulet Corporation • NASDAQ
$327.19 ▲ 0.12% (+0.39)
Market Cap $23.02 B
52w High $354.88
52w Low $230.05
Dividend Yield 0%
P/E 95.11
Volume 224.66K
Outstanding Shares 70.35M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $706.3M ▲ $392.4M ▲ $87.6M ▲ 12.403% ▲ $1.24 ▲ $160.4M ▲
Q2-2025 $649.1M ▲ $331.1M ▲ $22.5M ▼ 3.466% ▼ $0.32 ▼ $70.3M ▼
Q1-2025 $569M ▼ $320.2M ▼ $35.4M ▼ 6.221% ▼ $0.5 ▼ $79M ▼
Q4-2024 $597.5M ▲ $321.6M ▲ $100.7M ▲ 16.854% ▲ $1.44 ▲ $141.5M ▲
Q3-2024 $543.9M $289M $77.5M 14.249% $1.11 $116.5M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $757.4M ▼ $3.029B ▼ $1.645B ▼ $1.384B ▼
Q2-2025 $1.122B ▼ $3.469B ▼ $2.006B ▼ $1.463B ▲
Q1-2025 $1.283B ▲ $3.517B ▲ $2.187B ▲ $1.331B ▲
Q4-2024 $953.4M ▲ $3.088B ▲ $1.876B ▼ $1.212B ▲
Q3-2024 $902.6M $3.025B $1.907B $1.118B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $87.6M ▲ $125.7M ▼ $-31M ▼ $-457M ▼ $-364.2M ▼ $104.7M ▼
Q2-2025 $22.5M ▼ $196.5M ▲ $-23.2M ▼ $-343.6M ▼ $-161.5M ▼ $173.3M ▲
Q1-2025 $35.4M ▼ $63.8M ▼ $-15.7M ▲ $277.8M ▲ $329.7M ▲ $51.5M ▼
Q4-2024 $100.7M ▲ $147.7M ▲ $-68M ▼ $-20.9M ▼ $50.8M ▼ $91.7M ▲
Q3-2024 $77.5M $98.5M $-29.3M $7.8M $81.6M $71.8M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Drug Delivery
Drug Delivery
 $20.00M ▲$10.00M ▼$10.00M ▲$10.00M ▲
International Omnipod
International Omnipod
 $1.07Bn ▲$550.00M ▼$640.00M ▲$700.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown strongly and consistently over the last five years, with profitability scaling alongside it. Margins have improved as gross profit has risen faster than sales, suggesting good pricing power and operating discipline. Operating income has moved from barely profitable to clearly profitable, which is a healthy sign of maturity. Net income and earnings per share have stepped up sharply in the last two years, likely helped by both better operations and some non‑operating factors, so the most recent jump may not be fully repeatable every year. Overall, the income statement shows a business successfully growing its core franchise while becoming more efficient over time.

Balance Sheet

Balance Sheet The balance sheet shows a company that has expanded its asset base steadily while maintaining a solid cash cushion. Debt levels are meaningful but have not spiraled, and recent growth in shareholder equity suggests the financial foundation is getting stronger. The combination of good cash on hand and rising equity indicates improving resilience, even though leverage is still a consideration. Investments in facilities and technology are visible in the growing asset base, which should support future volume and innovation if demand holds up.

Cash Flow

Cash Flow Cash generation has improved notably. Operating cash flow has shifted from weak or negative to clearly positive, showing that growth is now translating into real cash, not just accounting profits. Free cash flow has moved from a period of cash burn to consistent positive territory, even while the company continues to invest in manufacturing and technology. This pattern suggests a business that has passed the heaviest investment phase and can increasingly fund its own growth, assuming performance remains on track.

Competitive Edge

Competitive Edge Insulet holds a differentiated position in diabetes care, centered on its tubeless Omnipod system and strong user experience. The pay‑as‑you‑go pharmacy model, high customer retention, and a large patent portfolio together create meaningful barriers to entry. Automated, wearable insulin delivery that integrates with leading glucose monitors gives the company a defensible niche versus traditional tubed pumps. At the same time, it faces real competition from other pump makers, evolving glucose monitoring ecosystems, and broader shifts in diabetes treatment such as newer drugs that may change insulin usage patterns. Its moat looks solid today, but it will need to keep executing well to maintain that edge as the landscape evolves.

Innovation and R&D

Innovation and R&D Innovation is clearly a core pillar: the roadmap includes upgrades to Omnipod 5, a next‑generation Omnipod 6 platform, and a fully closed‑loop system tailored to people with type 2 diabetes. Plans to integrate with multiple glucose monitoring systems and to use data and machine learning to personalize therapy deepen the technology angle. The company is also exploring its pod platform for other injectable drugs, which could diversify revenue beyond insulin over time. This opportunity set is attractive but comes with execution and regulatory risk; timelines, approvals, and real‑world adoption will determine how much of the pipeline turns into durable revenue and profit.

Summary

Insulet combines strong top‑line growth with improving profitability and increasingly healthy cash generation, signaling a business model that is scaling well. Its balance sheet has strengthened, with growing equity and solid liquidity, although debt remains an important factor to watch. The company appears to enjoy a real competitive moat in tubeless insulin delivery, supported by technology, brand, patents, and a distinctive distribution model. A rich innovation pipeline could extend its lead and broaden its addressable market, but success will depend on sustained clinical performance, regulatory progress, payer support, and the impact of new diabetes therapies on insulin demand. Overall, the profile is that of a focused medical device company with a strong niche, improving financial quality, and meaningful—but manageable—strategic and execution risks.

NEWS

November 20, 2025 · 12:30 PM UTC

Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day

Read more

November 6, 2025 · 6:30 AM UTC

Insulet Reports Third Quarter 2025 Results

Read more

October 30, 2025 · 4:00 AM UTC

Insulet Champions Workplace Inclusion for People with Diabetes with New Data and Tools Released for Diabetes Awareness Month

Read more

October 23, 2025 · 7:00 AM UTC

Insulet Announces Appointment of Robert L. Huffines to its Board of Directors

Read more

October 10, 2025 · 7:00 AM UTC

Insulet to Host Investor Day on November 20, 2025

Read more